CRC Research Update — September 21, 2026
Today's colorectal cancer research highlights
adjuvant
A collection of 50 issues
Oxaliplatin-Induced Neuropathy Tracked in Survivors Up to 2 Years Post-Treatment
Skip to content
The CRC Digest
♥ LIVING WITH CRC
Oxaliplatin-Induced Neuropathy Tracked in Survivors Up to 2 Years Post-Treatment
A prospective study of 106 stage II-III colon cancer patients treated with adjuvant CAPOX examined associations between oxaliplatin dosing and chemotherapy-induced peripheral neuropathy, with assessments continuing up to 24 months after
PEGASUS Phase 2 Trial Tests ctDNA-Guided Adjuvant Therapy in Colon Cancer
Skip to content
The CRC Digest
◆ TRIAL DATA
PEGASUS Phase 2 Trial Tests ctDNA-Guided Adjuvant Therapy in Colon Cancer
A Phase 2 trial is evaluating whether circulating tumor DNA can guide adjuvant treatment decisions in colon cancer patients after surgery. (Oncodaily)
This content is informational only and does not constitute
CRC Research Update — September 20, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 19, 2026
Today's colorectal cancer research highlights
CRC Research Update — September 16, 2026
Today's colorectal cancer research highlights
Meta-analysis shows ctDNA after surgery strongly predicts recurrence risk
Skip to content
The CRC Digest
◇ RESEARCH
Meta-analysis shows ctDNA after surgery strongly predicts recurrence risk
A meta-analysis of seven prospective cohorts found that postoperative circulating tumor DNA positivity was associated with increased recurrence risk (pooled hazard ratio, 7.60; 95% CI, 4.70-12.31) after curative-intent colorectal cancer resection,
CRC Research Update — September 15, 2026
Today's colorectal cancer research highlights
AI algorithm stratifies stage II/IIIA colorectal cancer recurrence risk from standard pathology slides
Skip to content
The CRC Digest
◇ RESEARCH
AI algorithm stratifies stage II/IIIA colorectal cancer recurrence risk from standard pathology slides
HistoNav, a deep-learning algorithm analyzing H&E-stained tissue samples from 2,095 patients, identified low-, intermediate-, and high-risk groups with 5-year disease-specific survival rates of 93.2%, 84.
CRC Research Update — September 11, 2026
Today's colorectal cancer research highlights